Back to top
more

Cardiovascular Systems, Inc. (CSII)

(Delayed Data from NSDQ)

$39.49 USD

39.49
435,746

+1.98 (5.28%)

Updated May 3, 2019 04:00 PM ET

After-Market: $39.52 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

Cardiovascular Systems (CSII) Finishes ECLIPSE Trial Enrollment

Cardiovascular Systems' (CSII) ECLIPSE clinical trial data is likely to help physicians form an optimal treatment plan for patients with severely calcified coronary arteries.

Why Is NuVasive (NUVA) Down 15.9% Since Last Earnings Report?

NuVasive (NUVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why Is Medtronic (MDT) Down 6.1% Since Last Earnings Report?

Medtronic (MDT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Cardiovascular Systems (CSII) Ails From Soft Volume, Macro Woes

Tough competition and consistent net loss continue to pose threats to Cardiovascular Systems (CSII).

Abbott (ABT) to Expand Vascular Device Line With New Buyout

Abbott's (ABT) latest deal will help gain access to Cardiovascular System's leading atherectomy device to treat vascular disease.

Cardiovascular Systems (CSII) Q2 Earnings, Revenues Miss

With the announcement of the merger agreement with Abbott, Cardiovascular Systems (CSII) refrains from providing any update on the 2023 guidance.

Cardiovascular Systems (CSII) Reports Q2 Loss, Misses Revenue Estimates

Cardiovascular Systems (CSII) delivered earnings and revenue surprises of -33.33% and 2.70%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Cardiovascular Systems (CSII) Global Sales Up, Margin Woe Stays

Cardiovascular Systems (CSII) international revenues are showing strong growth in each of the key markets, including Japan, Europe, Asia Pacific and Canada.

Cardiovascular Systems (CSII) Q1 Earnings Miss, Revenues Top

The launch of the Scoreflex scoring balloon receives a positive response and generates over $1.7 million in sales during the first quarter for Cardiovascular Systems (CSII).

Cardiovascular Systems (CSII) Reports Q1 Loss, Tops Revenue Estimates

Cardiovascular Systems (CSII) delivered earnings and revenue surprises of -12.50% and 0.58%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Cardiovascular Systems (CSII) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Cardiovascular Systems (CSII) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why Is Cardiovascular Systems (CSII) Down 18.9% Since Last Earnings Report?

Cardiovascular Systems (CSII) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Cardiovascular Systems (CSII) Q4 Earnings, Revenues Miss Mark

According to Cardiovascular Systems (CSII), strong sequential growth in each of its segments is due to procedure recovery, focused commercial strategies and the launch of products.

Zynex Inc. (ZYXI) Tops Q2 Earnings and Revenue Estimates

Zynex Inc. (ZYXI) delivered earnings and revenue surprises of 14.29% and 0.92%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Neogen (NEOG) Q4 Earnings and Revenues Beat Estimates

Neogen (NEOG) delivered earnings and revenue surprises of 12.50% and 1.25%, respectively, for the quarter ended May 2022. Do the numbers hold clues to what lies ahead for the stock?

QuidelOrtho (QDEL) Stock Jumps 3.9%: Will It Continue to Soar?

QuidelOrtho (QDEL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Cardiovascular Systems (CSII) Up 0.9% Since Last Earnings Report: Can It Continue?

Cardiovascular Systems (CSII) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Cardiovascular Systems' (CSII) Q3 Earnings Top Estimates

Cardiovascular Systems' (CSII) third-quarter revenues declined year over year due to lower Coronary and peripheral revenues.

Cardiovascular Systems (CSII) Reports Q3 Loss, Lags Revenue Estimates

Cardiovascular Systems (CSII) delivered earnings and revenue surprises of 10.71% and 2%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Cardiovascular Systems (CSII) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Cardiovascular Systems (CSII) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The Zacks Analyst Blog Highlights Alcon, Zimmer Biomet, Cardiovascular Systems, Abbott and Intuitive Surgical

Alcon, Zimmer Biomet, Cardiovascular Systems, Abbott and Intuitive Surgical have been included in this Analyst Blog.

Urmimala Biswas headshot

3 Medical Product Stocks Poised to Beat This Earnings Season

Medical product companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how ALC, ZBH and CSII are poised ahead of their earnings releases.

Here's Why You Should Hold on to Cardiovascular Systems (CSII)

Investors are optimistic about Cardiovascular Systems' (CSII) robust international growth and upcoming launches.

Cardiovascular Systems' (CSII) Low Procedure Volume Dents Sales

Cardiovascular Systems (CSII) notes that recovery from the Delta variant has been suppressed by the emergence of the highly contagious Omicron variant.

Cardiovascular Systems (CSII) Finances New DCB Development

Per the terms of the deal, Cardiovascular Systems (CSII) is providing milestone-based financing to CVT for the development of coronary and peripheral DCBs.